Juvenile Idiopathic Arthritis

London, United Kingdom—The presence of depression in patients with juvenile idiopathic arthritis (JIA) is associated with more severe pain, and disability at baseline and in the future, according to data from the Childhood Arthritis Prospective Study (CAPS) presented at the 2016 European League Against Rheumatism Annual Congress in June.
A clearer picture is emerging of evidence-based, nondrug treatments for patients with juvenile idiopathic arthritis (JIA), thanks to a recent article on foot care for youth suffering from the common chronic condition—which is associated with pain, deformities, and malalignment in the feet—published online ahead of print.
Paris, France—Biologics are a welcome advance for the treatment of patients with rheumatoid arthritis. They appear to be safe in adults, but there is always heightened concern when it comes to the effects of immunosuppressants and biologics in children.
New recommendations for juvenile idiopathic arthritis (JIA) were published in 2013, updating the previous set of recommendations from 2011.
Canakinumab, rilonacept, and tocilizumab considered for the first time By Rosemary Frei, MSc New recommendations from the American College of Rheumatology for the treatment of patients with systemic juvenile idiopathic arthritis (JIA) have been published simultaneously in the October 2013 issues of Arthritis Care & Research (Hoboken) (Ringold S, et al. 2013;65:1551-1563) and Arthritis & Rheumatism (Ringold S, et al. 2013;65:2499-2512).
By Rosemary Frei, MSc Winnipeg, Manitoba—For the first time, a study has confirmed that acceptance of pain among patients with rheumatoid arthritis (RA) is a strong predictor of their engaging in the recommended 150 minutes or more of weekly moderate-to-vigorous physical activity for this patient population. Pain intensity does not appear to be a significant predictor for physical activity level in these patients.
By Mark Knight Medication use in patients with systemic juvenile idiopathic arthritis (JIA) is highly variable but is gradually shifting toward the increased use of biologic agents, according to presenters who participated at a symposium on the topic at the 2012 meeting of the American College of Rheumatology (ACR).
By Phoebe Starr An excellent response to etanercept (Enbrel) in patients with juvenile idiopathic arthritis (JIA) was significantly associated with younger age and less disability at disease onset, as well as less use of antirheumatic drugs before initiating etanercept.
By Phoebe Starr

Similar to adults, early aggressive treatment with a biologic therapy in children with polyarticular juvenile idiopathic arthritis (JIA) is beneficial in achieving remission, as demonstrated in the double-blind, randomized Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthri­tis (TREAT in JIA), which is one of the few studies to focus on children with JIA.

Results 1 - 9 of 9
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology